Eugia recalls one vancomycin lot after glass particle is found
By Staff Writer · Published 11/9/2026, 8:09:19 PM ET

Example vial label accompanying Eugia’s recall of vancomycin lot 3VM26026A. Retrieved November 9, 2026; check the lot and expiry on actual stock.
Product label published by the U.S. Food and Drug Administration · Official image source · FDA website reuse policyFacilities should check inventory for lot 3VM26026A and arrange return or replacement.
Eugia US LLC has recalled a lot of vancomycin injection after a glass particle was found inside a vial. The company dated its announcement November 6; FDA posted it November 9.
The recall covers lot 3VM26026A of the 1.25-gram, 30-mL single-dose product, expiring July 2028. Vials show NDC 55150-471-01; cartons show NDC 55150-471-10. The lot went to wholesalers nationwide September 2–15.
Facilities holding this lot should immediately halt its use, quarantine inventory, alert any further recipients and inform their healthcare professionals. Eugia is arranging returns or replacements. Return questions go to Qualanex at 800-505-9291 or recall@qualanex.com, weekdays, 7 a.m.–4 p.m. Central Standard Time.
Eugia reported no related adverse events when it announced the recall. It warned that glass particles could block blood vessels and cause serious harm or death.
What it means
This notice concerns a specific lot used in healthcare settings. Patients experiencing possible medicine-related problems should contact their healthcare provider. Eugia handles medical questions at 866-850-2876, option 2, weekdays, 8 a.m.–5 p.m. Eastern Standard Time.
Source
This State & Nation summary is based on Eugia US LLC via FDA’s original release, dated 2026-11-09. The reporting above is attributed to the official sources linked here.